Dr. Andrew Hendifar Presents Groundbreaking Cancer Research at American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Co-Authored by Akexis Founder Dr. Lingbing Zhang

On January 25, 2025 Akexis reported company’s Principal Investigator (PI), Dr. Andrew Hendifar, presented the results of a pivotal proof-of-concept cancer cachexia study at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (Press release, Akexis, JAN 25, 2025, View Source [SID1234656608]). The presentation highlighted findings from a paper co-authored by Akexis Founder and Chief Scientific Officer, Dr. Lingbing Zhang, which explores an innovative therapeutic approach for treating advanced-stage cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, titled "Effect of ketorolac on serum GDF-15 and IL-8 in patients with pancreatic cancer with cachexia" (Abstract ID: 241654), showcased breakthrough data on targeting immune dysfunction in cancer cachexia, a debilitating condition that affects many late-stage cancer patients. The findings represent a significant step forward in addressing immune imbalances linked to cachexia and advancing care for patients with gastrointestinal cancers.

"Presenting these findings at ASCO (Free ASCO Whitepaper) is a testament to the collaborative work between Akexis founder, Dr. Lingbing Zhang and Cedars-Sinai’s dedicated oncology team," said Dr. Hendifar. "Our study provides compelling insights into novel therapeutic approaches, potentially improving quality of life for patients experiencing the devastating effects of cancer cachexia."

Dr. Zhang added, "This work validates Akexis’s commitment to transforming cancer care through innovative treatments that target the destructive immune dysregulation. Our collaboration with leading clinical experts like Dr. Hendifar is essential to achieving this mission."

Akexis remains focused on advancing innovative cancer therapeutics designed to improve outcomes for patients with late-stage cancer. The company continues to invest in groundbreaking research and partnerships that push the boundaries of late-stage cancer care.